InsiderTrades

Form 4 for BSX Boston Scientific

Accepted 2025-07-02 00:00:00 ET · period of report 2025-07-01 · accession 0001225208-25-006331 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-07-02 2025-07-01 BSX Fitzgerald Joseph Michael EVP, Group Pres, Cardiology S - Sale+OE $106.97 -50.0K 178.3K -22% -$5.35M
D 2025-07-02 2025-07-01 BSX Fitzgerald Joseph Michael EVP, Group Pres, Cardiology M - OptEx $26.15 +50.0K 228.3K +28% +$1.31M
D 2025-07-02 2025-07-01 BSX Fitzgerald Joseph Michael EVP, Group Pres, Cardiology M - OptEx $0.00 -50.0K 200.0K -20% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-07-01 S D 50,000 $106.97 178,342 D — — (F2) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $106.66 to $107.37, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
2 Common Common Stock 2025-07-01 M A 50,000 $26.15 228,342 D — —
3 Derivative Stock Option (Right to Buy) 2025-07-01 M D 50,000 $0.00 200,000 D $26.15 · — to 2027-12-01 50,000 Common Stock (F4) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant.